Identification of Prognostic Factors and Regulatory Pathways in Porto-Sinusoidal Vascular Disorder.
Measured against the standard of care· AASLD/EASL/APASL/ALEH multisociety consensus 2026 (diagnosis) / AASLD 2021 vascular liver disorders guidance (management)
… PSVD/NCPF can coexist with another chronic liver disease as long as the biopsy shows no cirrhosis. … Minor histology is any of: regenerative changes without NRH, abnormal distribution of vascular structures, or portal venule stenosis in 25-49% of portal tracts. … A total of 2 or less means the diagnosis cannot be made, 3-4 is possible PSVD/NCPF (follow up and/or refer to an expert center), and 5 or more is confirmed. …
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standard
Diagnosis now follows the 2026 multisociety consensus (AASLD, EASL, APASL and ALEH, with the pathology and pediatric societies ESP, Hans Popper, SGIHPBPs, NASPGHAN and ESPGHAN). PSVD and NCPF are interchangeable names for one clinicopathological diagnosis. A liver biopsy is mandatory, and it must exclude cirrhosis. A specimen of at least 15 mm with at least one fragment of 10 mm or more is enough to do that. The listed alternative conditions must also be excluded. Signs of portal hypertension are no longer required for the diagnosis. PSVD/NCPF can coexist with another chronic liver disease as long as the biopsy shows no cirrhosis. Major histology is any of: NRH, muscularized portal venules, or portal venule stenosis in at least 50% of portal tracts. Minor histology is any of: regenerative changes without NRH, abnormal distribution of vascular structures, or portal venule stenosis in 25-49% of portal tracts. All three minor criteria together count as one major criterion. Specific signs of portal hypertension are variceal bleeding, medium or large esophageal varices, gastric varices, spontaneous portosystemic shunts, spleen stiffness above 40 kPa without an MPN, and HVPG or porto-caval gradient of 10 mmHg or more. Non-specific signs are clinical ascites, small varices, platelets below 150 G/L and splenomegaly. Scoring takes only the highest item in each domain. Portal hypertension scores 0 if absent, 2 if only non-specific signs, 3 if any specific sign. Histology scores 0 if normal, 2 for up to two minor criteria, 5 for any major criterion or all three minor. An associated condition adds 1. A concomitant cause of cirrhosis subtracts 1; metabolic syndrome without biopsy-proven MASLD does not count. A total of 2 or less means the diagnosis cannot be made, 3-4 is possible PSVD/NCPF (follow up and/or refer to an expert center), and 5 or more is confirmed. Low liver stiffness with high spleen stiffness, MRI periportal hyperintensity, or a nodular surface with a normal or enlarged segment IV add suspicion but no points. Three former exclusions were dropped. An intrahepatic portal cavernoma no longer excludes the diagnosis. SOS diagnosed more than 6 months earlier after stem cell transplant no longer excludes it. In endemic areas without hepatosplenic schistosomiasis, positive schistosomal serology or a few eggs on biopsy no longer exclude it. The consensus does not cover management, so management is unchanged from AASLD 2021. Look for associated conditions and causes: drugs, MPN, thrombophilia, PNH, autoimmune disease, CVID, HIV. Manage portal hypertension complications as in cirrhosis: NSBB (carvedilol preferred) or EVL for variceal prophylaxis, and TIPS for refractory or recurrent bleeding. Stop offending drugs and treat the specific cause. Decide on anticoagulation for coexisting PVT case by case, weighing thrombus acuity, bleeding risk and cause. Reserve liver transplant for refractory complications. HCC surveillance is not routine without cirrhosis.